Filter by Year:
Press Releases
-
Jul 08, 2020
Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target
-
Jan 09, 2020
Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors
-
Sep 16, 2019
Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments
-
Dec 13, 2018
Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer
-
Mar 14, 2018
Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million
Displaying 61 - 65 of 65